Physician profile
James Pease
NPI 1811074321
$628.24
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $505 · 2020: $95.82 · 2022: $27.88.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $127.68 | 2019-2020 | |
| Novo Nordisk INC | $98.56 | 2019-2020 | |
| Intuitive Surgical, INC. | $58.21 | 2019 | |
| Pfizer INC. | $53.54 | 2019-2022 | |
| Astellas Pharma US INC | $33.60 | 2019 | |
| Sunovion Pharmaceuticals INC. | $33.11 | 2019 | |
| Sanofi-Aventis U.S. LLC | $24.09 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $22.06 | 2019 | |
| Sanofi Pasteur INC. | $15.54 | 2019 | |
| Allergan, INC. | $15.17 | 2020 | |
| Daiichi Sankyo INC. | $13.84 | 2019 | |
| Radius Health, INC. | $13.14 | 2019 | |
| Amarin Pharma, INC. | $13.14 | 2019 | |
| Glaxosmithkline, LLC. | $12.85 | 2020 | |
| Janssen Pharmaceuticals, INC | $12.83 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $12.39 | 2019 | |
| Abbott Laboratories | $12.37 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.72 | 2019 | |
| Avanir Pharmaceuticals, INC. | $11.54 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $11.25 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $10.82 | 2019 | |
| Arbor Pharmaceuticals, INC. | $10.79 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Pease listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.